Usefulness of 6-minute walk test, plasma neurohumoral and cytokine activation in the assessment of symptomatic patients with left ventricle dysfunction caused by chronic severe mitral valve regurgitation

Objective — The aim of our study was to select the most relevant markers of impaired left ventricle (LV) function in patients with heart failure (HF) symptoms due to severe chronic mitral regurgitation (MR). Methods and results—Thirty-six patients with decompensated HF due to severe MR underwent echocardiography, 6-minute walk test (6MWT) and measurements of plasma renin activity, angiotensin II, aldosterone, noradrenaline (NA), brain natriuretic peptide (BNP), tumour necrosis factor a (TNFa) with its receptors, and interleukine-6. Patients presented with significant neurohumoral/cytokine activation. By stepwise multiple regression analysis the strongest prediction model for 6MWT included LVEDVI (R2 = 0.95, P = 0.024), BNP (R2 = 0.67, P = 0.0006), IL-6 (R2 = 0.90, P = 0.044); for BNP: 6MWT (R2 = 0.36, P = 0.003), LA (R2 = 0.56, P = 0.0077), LVESVI (R2 = 0.83, P = 0.0072); for NA : EF (R2 = 0.41, P = 0.036), and for TNFa: LVESVI (R2 = 0.65, P = 0.003). Conclusions — 6MWT and neurohumoral markers (mainly BNP, but also NA and TNFa) are good predictors of the degree of LV remodelling, showing an independent correlation with the level of LV dilatation/dysfunction in chronic severe MR.These assessments may supplement standard echocardiography in LV decompensation due to severe MR.

[1]  B. Keevil,et al.  Utility of plasma N-terminal brain natriuretic peptide as a marker of functional capacity in patients with chronic severe mitral regurgitation. , 2006, The American journal of cardiology.

[2]  M. Enriquez-Sarano,et al.  B-Type Natriuretic Peptide in Organic Mitral Regurgitation: Determinants and Impact on Outcome , 2005, Circulation.

[3]  S. Aydoǧdu,et al.  Plasma brain natriuretic peptide levels in patients with rheumatic heart disease , 2004, European journal of heart failure.

[4]  Masazumi Watanabe,et al.  Is measurement of plasma brain natriuretic peptide levels a useful test to detect for surgical timing of valve disease? , 2004, International journal of cardiology.

[5]  S. Murphy,et al.  Comparison of B-type natriuretic peptide levels in patients with heart failure with versus without mitral regurgitation. , 2004, American Journal of Cardiology.

[6]  H. Oral,et al.  Changes in systemic sympathetic nervous system activity after mitral valve surgery and their relationship to changes in left ventricular size and systolic performance in patients with mitral regurgitation. , 2004, American heart journal.

[7]  J. Korewicki,et al.  Mitral valve regurgitation and plasma neurohumoral and cytokine activation. , 2004, Acta cardiologica.

[8]  R. Razzolini,et al.  Plasma levels of tumor necrosis factor-alpha correlate with the six-minute walk test results in patients with mild to moderate heart failure. , 2004, Italian heart journal : official journal of the Italian Federation of Cardiology.

[9]  B. Carabello Indications for mitral valve surgery. , 2004, The Journal of cardiovascular surgery.

[10]  A. Kerr,et al.  Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. , 2003, Journal of the American College of Cardiology.

[11]  H. Oral,et al.  Compared with control subjects, the systemic sympathetic nervous system is activated in patients with mitral regurgitation. , 2003, American heart journal.

[12]  M. Desnos,et al.  Bedside B‐type natriuretic peptide and functional capacity in chronic heart failure , 2003, European journal of heart failure.

[13]  S. Bolling,et al.  Myocardial Proinflammatory Cytokine Expression and Left Ventricular Remodeling in Patients With Chronic Mitral Regurgitation , 2003, Circulation.

[14]  B. Carabello The Ten Most Commonly Asked Questions About Mitral Regurgitation , 2002, Cardiology in review.

[15]  Y. Yazaki,et al.  Measurement of plasma brain natriuretic peptide level as a guide for cardiac overload. , 2001, Cardiovascular research.

[16]  M. J. Smith,et al.  Relation of systemic sympathetic nervous system activation to echocardiographic left ventricular size and performance and its implications in patients with mitral regurgitation. , 2000, The American journal of cardiology.

[17]  P. De Groote,et al.  Effect of mitral valve surgery on exercise capacity, ventricular ejection fraction and neurohormonal activation in patients with severe mitral regurgitation. , 2000, Journal of the American College of Cardiology.

[18]  J. Thomas,et al.  Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. , 2000, Journal of the American College of Cardiology.

[19]  B. Carabello,et al.  Chronic mitral regurgitation: when and how to operate. , 1998, Chest.

[20]  Y. Kihara,et al.  Marked elevation of brain natriuretic peptide levels in pericardial fluid is closely associated with left ventricular dysfunction. , 1998, Journal of the American College of Cardiology.

[21]  N. Moat,et al.  Plasma brain natriuretic peptide concentrations in patients with chronic mitral regurgitation. , 1997, The Journal of heart valve disease.

[22]  H. Oral,et al.  Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). , 1996, Journal of the American College of Cardiology.

[23]  N. Dzimiri,et al.  Comparison of the effect of left ventricular volume and pressure overload on beta-adrenoceptor density in left heart valvular disease. , 1996, International journal of cardiology.

[24]  D. Mann,et al.  Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. , 1996, Circulation.